Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model

被引:44
作者
Dougherty, Urszula [1 ]
Sehdev, Arnikar [1 ]
Cerda, Sonia [1 ]
Mustafi, Reba [1 ]
Little, Nathaniel [1 ]
Yuan, Weihua [1 ]
Jagadeeswaran, Sujatha [1 ]
Churnsangsri, Anusara [1 ]
Delgado, Jorge [1 ]
Tretiakova, Maria [3 ]
Joseph, Loren [3 ]
Hart, John [3 ]
Cohen, Ezra E. W. [1 ,3 ]
Aluri, Lata [1 ]
Fichera, Alessandro [2 ]
Bissonnette, Marc [1 ]
机构
[1] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Surg, Chicago, IL 60637 USA
[3] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA
关键词
D O I
10.1158/1078-0432.CCR-07-4926
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Colonic carcinogenesis deranges growth-regulating epidermal growth factor receptors (EGFR). We previously showed that EGFR signals were up-regulated in human aberrant crypt foci (ACF), putative colon cancer precursors. The azoxymethane model of colon cancer recapitulates many aspects of human colonic tumors. Recent studies indicate that flat dysplastic ACF with increased beta-catenin are tumor precursors in this model. We asked, therefore, if EGFR signals are required for flat clysplastic ACF development and cancer progression. Experimental Design: Rats received azoxymethane or saline, and standard chow or chow supplemented with gefitinib, an EGFR inhibitor, for 44 weeks. EGFR signals were quantified in normal colon, flat ACF, and tumors by computerized analysis of immunostains and Western blots. K-ras mutations were assessed by PCR and mRNA for egfr ligands by quantitative real-time PCR. Results: EGFR inhibition with gefitinib decreased the incidence of flat clysplastic ACF from 66% to 36% and tumors from 71% to 22% (P < 0.05). This inhibitor also reduced the overexpressions of cyclin D1 and Cox-2 in flat ACF. Furthermore, in flat ACF, EGFR blockade decreased the upregulation of c-Jun, Fos13, phosphorylated active signal transducers and activators of transcription 3, and CCAAT/enhancer binding protein-beta, potential regulators of cyclin D1 and Cox-2. In colonic tumors, EGFR blockade significantly decreased angiogenesis, proliferation, and progression while also increasing apoptosis (P < 0.05). Gefitinib also inhibited the activations of extracellular signal - regulated kinase, Src, and AKT pathways in tumors. Conclusions: We have shown for the first time that EGFR promotes the development of flat clysplastic ACF and the progression of malignant colonic tumors. Furthermore, we have mechanistically identified several transcription factors and their targets as EGFR effectors in colonic carcinogenesis.
引用
收藏
页码:2253 / 2262
页数:10
相关论文
共 61 条
[1]   Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas [J].
Adegboyega, PA ;
Ololade, O ;
Saada, J ;
Mifflin, R ;
Di Mari, JF ;
Powell, DW .
CLINICAL CANCER RESEARCH, 2004, 10 (17) :5870-5879
[2]   Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27(KIP1) [J].
Aktas, H ;
Cai, H ;
Cooper, GM .
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (07) :3850-3857
[3]   TRANSFORMING P21(RAS) MUTANTS AND C-ETS-2 ACTIVATE THE CYCLIN D1 PROMOTER THROUGH DISTINGUISHABLE REGIONS [J].
ALBANESE, C ;
JOHNSON, J ;
WATANABE, G ;
EKLUND, N ;
VU, D ;
ARNOLD, A ;
PESTELL, RG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (40) :23589-23597
[4]  
Araki Y, 2003, CANCER RES, V63, P728
[5]   Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].
Baselga, J ;
Rischin, D ;
Ranson, M ;
Calvert, H ;
Raymond, E ;
Kieback, DG ;
Kaye, SB ;
Gianni, L ;
Harris, A ;
Bjork, T ;
Averbuch, SD ;
Feyereislova, A ;
Swaisland, H ;
Rojo, F ;
Albanell, J .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302
[6]  
Bissonnette M, 2000, CANCER RES, V60, P4602
[7]   Pathology of mouse models of intestinal cancer: Consensus report and recommendations [J].
Boivin, GP ;
Washington, K ;
Yang, K ;
Ward, JM ;
Pretlow, TP ;
Russell, R ;
Besselsen, DG ;
Godfrey, VL ;
Doetschman, T ;
Dove, WF ;
Pitot, HC ;
Halberg, RB ;
Itzkowitz, SH ;
Groden, J ;
Coffey, RJ .
GASTROENTEROLOGY, 2003, 124 (03) :762-777
[8]   Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer [J].
Buchanan, F. Gregory ;
Holla, Vijay ;
Katkuri, Sharada ;
Matta, Pranathi ;
DuBois, Raymond N. .
CANCER RESEARCH, 2007, 67 (19) :9380-9388
[9]   The induction of cyclooxygenase-2 mRNA in macrophages is biphasic and requires both CCAAT enhancer-binding protein β (C/EBPβ) and C/EBPδ transcription factors [J].
Caivano, M ;
Gorgoni, B ;
Cohen, P ;
Poli, V .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (52) :48693-48701
[10]   Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis [J].
Chan, KS ;
Carbajal, S ;
Kiguchi, K ;
Clifford, J ;
Sano, S ;
DiGiovanni, J .
CANCER RESEARCH, 2004, 64 (07) :2382-2389